Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gurlek, A.
Right arrow Articles by Kirazli, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gurlek, A.
Right arrow Articles by Kirazli, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 23, Issue 1 88-92, Copyright © 2000 by American Diabetes Association

ARTICLES

Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels

A Gurlek, M Bayraktar and S Kirazli
Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey. agurlek@ato.org.tr

OBJECTIVE: To determine whether a dysregulation of the fibrinolytic system exists in normal glucose tolerant offspring of type 2 diabetic patients. RESEARCH DESIGN AND METHODS: In this cross-sectional study, 32 offspring of type 2 diabetic patients and 26 subjects with no family history of diabetes were studied. With respect to the metabolic parameters, plasma fasting and 2-h postload (75 g glucose) glucose and insulin levels, total cholesterol, triglycerides, and HDL cholesterol concentrations were determined. To evaluate the status of hemostatic factors, fibrinogen, tissue plasminogen activator (tPA) antigen level, plasminogen activator inhibitor-1 (PAI-1) antigen level, and PAI-1 activity were assessed. The statistical analyses included the Mann-Whitney U test to check the significance of differences between variables in the two groups and Spearman's rank correlation tests to check the interrelationships between the hemostatic and metabolic parameters in the offspring group. RESULTS: All subjects had normal glucose tolerance according to the American Diabetes Association criteria. Plasma fasting and postload insulin concentrations were significantly higher in offspring compared with control group (P<0.00001 and P<0.01, respectively). Plasma fasting and postload glucose, fibrinogen, tPA antigen, total cholesterol, and BMI were comparable between the groups. The offspring had significantly higher waist-to-hip ratio (WHR) (P = 0.03), higher triglycerides (P = 0.01), and lower HDL cholesterol (P<0.01) compared with the control group. PAI-1 antigen level and PAI-1 activity were higher in the offspring (P = 0.05 and P = 0.04, respectively). In the offspring group, PAI-1 activity was correlated with plasma PAI-1 antigen level (r = 0.40, P = 0.02), fibrinogen (r = 0.45, P = 0.01), and HDL cholesterol (r = -0.36, P = 0.04). However, tPA antigen level, fasting and postload plasma glucose and insulin, total cholesterol, triglycerides, WHR, and BMI did not correlate with PAI-1 activity. CONCLUSIONS: These data suggest that normal glucose tolerant offspring of type 2 diabetic subjects have elevated PAI-1 activity indicating to hypofibrinolysis in this group. The elevated PAI-1 activity has no association with plasma insulin concentration.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. Agirbasli, A. Cincin, and O. A Baykan
Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 22 - 26.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
X. Liang, T. Kanjanabuch, S.-L. Mao, C.-M. Hao, Y.-W. Tang, P. J. Declerck, A. H. Hasty, D. H. Wasserman, A. B. Fogo, and L.-J. Ma
Plasminogen activator inhibitor-1 modulates adipocyte differentiation
Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E103 - E113.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L.-J. Ma, S.-L. Mao, K. L. Taylor, T. Kanjanabuch, Y. Guan, Y. Zhang, N. J. Brown, L. L. Swift, O. P. McGuinness, D. H. Wasserman, et al.
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Diabetes, February 1, 2004; 53(2): 336 - 346.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
N. Pannacciulli, G. De Pergola, M. Ciccone, P. Rizzon, F. Giorgino, and R. Giorgino
Effect of Family History of Type 2 Diabetes on the Intima-Media Thickness of the Common Carotid Artery in Normal-Weight, Overweight, and Obese Glucose-Tolerant Young Adults
Diabetes Care, April 1, 2003; 26(4): 1230 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
L. Iacoviello, E. Ciccarone, and M. B. Donati
Review: The genetics of macrovascular disease in diabetes
The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 364 - 368.
[Abstract] [PDF]

Home page
 DiabetesHome page
A. Festa, R. D'Agostino Jr, R. P. Tracy, and S. M. Haffner
Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes: The Insulin Resistance Atherosclerosis Study
Diabetes, April 1, 2002; 51(4): 1131 - 1137.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2000 by the American Diabetes Association.